Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality worldwide. This retrospective observational study evaluated the antibiotic prescription patterns and associations between guideline adherence and outcomes in patients hospitalized with CAP in Hungary. Main outcome measures were adherence to national and international CAP guidelines (agent choice, dose) when using empirical antibiotics, antibiotic exposure, and clinical outcomes. Demographic and clinical characteristics of patients with CAP in the 30-day mortality and 30-day survival groups were compared. Fisher’s exact test and t-test were applied to compare categorical and continuous variables, respectively. Adherence to the national CAP guideline for initial empirical therapies was 30.61% (45/147) for agent choice and 88.89% (40/45) for dose. Average duration of antibiotic therapy for CAP was 7.13 ± 4.37 (mean ± SD) days, while average antibiotic consumption was 11.41 ± 8.59 DDD/patient (range 1−44.5). Adherence to national guideline led to a slightly lower 30-day mortality rate than guideline non-adherence (15.56% vs. 16.67%, p > 0.05). In patients aged ≥ 85 years, 30-day mortality was 3 times higher than in those aged 65−84 years (30.43% vs. 11.11%). A significant difference was found between 30-day non-survivors and 30-day survivors regarding the average CRP values on admission (177.28 ± 118.94 vs. 112.88 ± 93.47 mg/L, respectively, p = 0.006) and CCI score (5.71 ± 1.85 and 4.67 ± 1.83, p = 0.012). We found poor adherence to the national and international CAP guidelines in terms of agent choice. In addition, high CRP values on admission were markedly associated with higher mortality in CAP.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026550PMC
http://dx.doi.org/10.3390/antibiotics11040468DOI Listing

Publication Analysis

Top Keywords

adherence national
16
agent choice
12
30-day mortality
12
cap
9
guideline adherence
8
adherence outcomes
8
outcomes patients
8
patients hospitalized
8
community-acquired pneumonia
8
pneumonia cap
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Fleni, Buenos Aires, Buenos Aires, Argentina.

Background: The LatAm-FINGERS trial marks a pioneering initiative as the first non-pharmacological clinical trial encompassing participants from 12 Latin American countries, including Argentina, Brazil, Bolivia, Chile, Colombia, Costa Rica, Ecuador, Dominican Republic, Mexico, Peru, Puerto Rico, and Uruguay. This initiative represents a significant advancement in promoting inclusivity and diversity in clinical trial recruitment, particularly in underserved populations.

Method: The LatAm-FINGERS trial is a multicenter randomized clinical trial evaluating a lifestyle intervention tailored for the Latin American population.

View Article and Find Full Text PDF

Background: LatAm-FINGERS is the first non-pharmacological multicenter randomized clinical trial aimed at preventing cognitive impairment in Latin America. It encompasses twelve countries that collectively represent 45% of the territory in the Americas. Its objective is to reach populations that, despite sharing commonalities such as language, are culturally and economically diverse.

View Article and Find Full Text PDF

Background: Alzheimer's disease is estimated to reach 139 million people by 2050, with an increase in people living with functional limitations caused by the disease (Alzheimer's Disease International). However, telerehabilitation presents a promising solution to improve functional outcomes in patients with Alzheimer's disease. This systematic review investigates the use of telerehabilitation therapies worldwide for the treatment of Alzheimer's disease and cognitive impairments.

View Article and Find Full Text PDF

Dementia Care Practice.

Alzheimers Dement

December 2024

Henry Ford Health, Detroit, MI, USA.

Introduction: Alzheimer's disease is the most common and costly neurodegenerative disease worldwide. Early studies of helmet-based 40 Hz light therapy have demonstrated safety and early efficacy in targeting the pathophysiologic characteristics of Alzheimer's disease. This intervention has shown slowing and even reversal of disease progression.

View Article and Find Full Text PDF

Background: Advances in the development of e-health applications enhance the availability of preventive tools and the adherence to certain treatments in old age (Roberts et al., 2015; Granath et al., 2023).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!